| Style | Citing Format |
|---|---|
| MLA | Ghahvehchian H, Eshraghi B. "Tofacitinib for Refractory Thyroid Eye Disease." JAMA Ophthalmology, vol. 143, no. 12, 2025, pp. 1073-1075. |
| APA | Ghahvehchian H, Eshraghi B (2025). Tofacitinib for Refractory Thyroid Eye Disease. JAMA Ophthalmology, 143(12), 1073-1075. |
| Chicago | Ghahvehchian H, Eshraghi B. "Tofacitinib for Refractory Thyroid Eye Disease." JAMA Ophthalmology 143, no. 12 (2025): 1073-1075. |
| Harvard | Ghahvehchian H, Eshraghi B (2025) 'Tofacitinib for Refractory Thyroid Eye Disease', JAMA Ophthalmology, 143(12), pp. 1073-1075. |
| Vancouver | Ghahvehchian H, Eshraghi B. Tofacitinib for Refractory Thyroid Eye Disease. JAMA Ophthalmology. 2025;143(12):1073-1075. |
| BibTex | @article{ author = {Ghahvehchian H and Eshraghi B}, title = {Tofacitinib for Refractory Thyroid Eye Disease}, journal = {JAMA Ophthalmology}, volume = {143}, number = {12}, pages = {1073-1075}, year = {2025} } |
| RIS | TY - JOUR AU - Ghahvehchian H AU - Eshraghi B TI - Tofacitinib for Refractory Thyroid Eye Disease JO - JAMA Ophthalmology VL - 143 IS - 12 SP - 1073 EP - 1075 PY - 2025 ER - |